ClinicalTrials.gg
CompletedNCT03727880Updated Feb 4, 2026Results posted

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

A Phase 2 interventional study of Pembrolizumab and Defactinib in Resectable Pancreatic Ductal Adenocarcinoma (PDAC) and Pancreatic Ductal Adenocarcinoma, sponsored by Lei Zheng. Completed at 3 sites in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Lei Zheng · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,850 studies in Pancreatic Neoplasms with a site in United States — 297 open to participants now, 469 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Enrollment
911th of 1,573
28 · median 37
Started
2019
with 93 others
Phase 2
488 of 1,850
45 open now
Registered
1,197th of 1,850
by date

Among the 1,850 studies in Pancreatic Neoplasms with a site in United States, this one is the 911th largest by enrollment of the 1,573 interventional ones that give a count, is one of 94 that started in 2019, is one of 488 in phase 2, and was the 1,197th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

297 of the 1,850 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

292 more — sign in →

All 297 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,850 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study will test the effectiveness (anti-tumor activity), safety, and ability to increase the body's immune system to fight pancreatic cancer by combining standard chemotherapy before and after surgery, with study drug PD-1 antibody, pembrolizumab, with and without study drug, focal adhesion kinase inhibitor (FAK), defactinib, in people with "high risk" resectable (surgically removable) pancreatic cancer. The purpose of this study is to evaluate if reprograming the tumor microenvironment by targeting FAK following chemotherapy can potentiate anti-programmed death-1 (PD-1) antibody.

03

Conditions studied

  • Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
  • Pancreatic Ductal Adenocarcinoma

Keywords

  • Pembrolizumab
  • Defactinib
  • Immunotherapy
  • Anti-PD-1
  • Antibody
  • PD-L1
  • Pancreatic cancer
  • Neoadjuvant chemotherapy
  • Adjuvant chemotherapy
  • PDAC - Pancreatic Ductal Adenocarcinoma
  • FAK (focal adhesion kinase) inhibitor
  • Resectable Pancreatic Adenocarcinoma
  • High Risk Resectable Pancreatic Cancer
  • Tumor microenvironment
  • CA 19-9
  • Surgery
  • Pancreatectomy
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • Has pancreatic ductal adenocarcinoma
  • Has resectable disease at the time of diagnosis
  • Has not received any systemic therapy for pancreatic ductal adenocarcinoma
  • Has stage ≤ IIb disease at time of diagnosis and enrollment
  • Elevated tumor marker, CA (carbohydrate antigen) 19-9 >200
  • performance status 0 or 1
  • Patient must have adequate organ function defined by the study-specified laboratory tests.
  • Must use acceptable form of while on study.
  • Ability to understand and willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

Patients who have received any prior chemotherapy, radiotherapy or agents for pancreatic cancer.

  • Patients who have received prior treatment with , anti-PD-L1, anti-PD-L2, anti-CTLA-4, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137).
  • Has received prior therapy with FAK inhibitor.
  • Woman who are pregnant or breastfeeding.
  • Have received a or live-attenuated vaccine within 30 days prior to study drug.
  • Is currently or has participated in another investigational study within 4 weeks prior to receiving study drug.
  • History or current use of medications within 7 days prior to study medications.
  • Has a known additional that is progressing or has required active treatment within the past 2 years or that is expected to require active treatment within two years.
  • Has active disease that has required systemic treatment in the past 2 years.
  • Has a history of (non-infectious) pneumonitis/interstitial lung disease or current pneumonitis.
  • Has an active infection requiring systemic therapy.
  • Infection with or or C.
  • Patient with uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Known allergy or to the study drugs.
  • Received any growth factors including, but not limited to, granulocyte-colony stimulating factor (G-CSF), GM-CSF, erythropoietin, within 14 days of study drug administration.
  • Has history of any organ transplant, including corneal transplants.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Arm A - Pembrolizumab and Defactinib

    Drug: Pembrolizumab · Drug: Defactinib

  • Experimental
    Arm B - Pembrolizumab

    Drug: Pembrolizumab

Interventions

  • Following standard of care neoadjuvant chemotherapy, subjects will receive two doses of pembrolizumab (200mg) IV 3 weeks apart prior to surgery. After surgery, subjects will receive adjuvant standard of care chemotherapy. Following adjuvant chemotherapy, subjects will receive 8 doses of pembrolizumab (200mg) IV 3 weeks apart.

    Also known as: MK-3475, Keytruda

  • Following 2 cycles of standard of care neoadjuvant chemotherapy, subjects will receive 400 mg defactinib twice a day up until 2 days preceding their surgery (approximately 6 weeks) during the immunotherapy cycles with pembrolizumab. After surgery, subjects will receive adjuvant standard of care chemotherapy. Following adjuvant chemotherapy, subjects will receive 400mg defactinib twice a day for 24 weeks.

06

What researchers measure

Primary outcomes

  1. Pathologic Complete Response (pCR) Rate

    Percent of subjects with a pathologic complete response (pCR) per the tumor regression grade scores established by the College of American Pathologist: Grade 0= complete response (no viable cancer cells), Grade 1= near complete response (single cells or rare small groups of cancer cells), Grade 2= partial response (residual tumor with evidence of regression), or Grade 3= no response (extensive residual tumor with no evidence of regression).

    Time frame: 4 years

Secondary outcomes

  1. Overall Survival (OS)

    Number of months until death

    Time frame: 4 years

  2. Disease Free Survival (DFS)

    Number of months until disease recurrence

    Time frame: 4 years

  3. Number of Participants Experiencing Study Drug-related Toxicities

    Number of participants experiencing drug-related adverse events as defined by CTCAE v5.0

    Time frame: 4 years

07

Results

Posted Feb 4, 2026

Participant flow

Participant flow — Overall Study
MilestoneArm A - Pembrolizumab and DefactinibArm B - Pembrolizumab
Started1414
Completed1310
Not completed14

Outcome measures

PrimaryPathologic Complete Response (pCR) Rate

Percent of subjects with a pathologic complete response (pCR) per the tumor regression grade scores established by the College of American Pathologist: Grade 0= complete response (no viable cancer cells), Grade 1= near complete response (single cells or rare small groups of cancer cells), Grade 2= partial response (residual tumor with evidence of regression), or Grade 3= no response (extensive residual tumor with no evidence of regression).

Time frame:
4 years
Reported as:
Number · Percentage of participants
Pathologic Complete Response (pCR) Rate
Percentage of participantsArm A - Pembrolizumab and DefactinibArm B - Pembrolizumab
Pathologic Complete Response (pCR) Rate00
SecondaryOverall Survival (OS)

Number of months until death

Time frame:
4 years
Reported as:
Mean · months
Overall Survival (OS)
monthsArm A - Pembrolizumab and DefactinibArm B - Pembrolizumab
Overall Survival (OS)25.01 ± 14.4827.39 ± 19.54
SecondaryDisease Free Survival (DFS)

Number of months until disease recurrence

Time frame:
4 years
Reported as:
Mean · months
Disease Free Survival (DFS)
monthsArm A - Pembrolizumab and DefactinibArm B - Pembrolizumab
Disease Free Survival (DFS)16.59 ± 14.3315.99 ± 15.20
SecondaryNumber of Participants Experiencing Study Drug-related Toxicities

Number of participants experiencing drug-related adverse events as defined by CTCAE v5.0

Time frame:
4 years
Reported as:
Number · participants
Number of Participants Experiencing Study Drug-related Toxicities
participantsArm A - Pembrolizumab and DefactinibArm B - Pembrolizumab
Number of Participants Experiencing Study Drug-related Toxicities63

Adverse events

Collected over Adverse events were collected from baseline to 4 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A - Pembrolizumab and Defactinib10/14 (71.4%)2/14 (14.3%)4/14 (28.6%)
Arm B - Pembrolizumab6/14 (42.9%)3/14 (21.4%)3/14 (21.4%)
Most frequent serious events
Most frequent serious events
EventArm A - Pembrolizumab and DefactinibArm B - Pembrolizumab
Non-pancreatic cancerGeneral disorders2/143/14
Most frequent other events
Most frequent other events
EventArm A - Pembrolizumab and DefactinibArm B - Pembrolizumab
Increased bilirubinBlood and lymphatic system disorders3/140/14
ColitisGastrointestinal disorders0/141/14
Elevated aspartate aminotransferase (AST)Hepatobiliary disorders1/140/14
Elevated Alanine transaminase (ALT)Hepatobiliary disorders1/140/14
Acnieform rashSkin and subcutaneous tissue disorders1/140/14
Myasthenia gravisMusculoskeletal and connective tissue disorders0/141/14
ArthralgiaMusculoskeletal and connective tissue disorders0/141/14

Baseline characteristics

Number of evaluable participants randomized to interventions

Age, Continuous
Age, Continuous(Years)Arm A - Pembrolizumab and DefactinibArm B - PembrolizumabTotal
Mean71.54 ± 11.3973.5 ± 6.6272.4 ± 9.01
Sex: Female, Male
Sex: Female, Male(Participants)Arm A - Pembrolizumab and DefactinibArm B - PembrolizumabTotal
Female639
Male7714
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A - Pembrolizumab and DefactinibArm B - PembrolizumabTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White101020
More than one race000
Unknown or Not Reported303
Region of Enrollment
Region of Enrollment(participants)Arm A - Pembrolizumab and DefactinibArm B - PembrolizumabTotal
United States131023
08

Study locations

3 sites
  • Samuel Oschin Cancer Center at Cedars-Sinai
    Los Angeles, California 90048, United States
  • Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland 21231, United States
  • The University of Texas Health Science Center San Antonio
    San Antonio, Texas 78229, United States
09

References and documents

Publications

  • Fard D, Giraudo E, Tamagnone L. Mind the (guidance) signals! Translational relevance of semaphorins, plexins, and neuropilins in pancreatic cancer. Trends Mol Med. 2023 Oct;29(10):817-829. doi: 10.1016/j.molmed.2023.07.009. Epub 2023 Aug 17. PubMed 37598000 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Jan 2025, 67 months.

Results were first posted in Feb 2026, 1 year after primary completion.

Of 327 non-industry phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 80. This study's 67 months is above that.

Counting every sponsor, half of 396 studies reached it within 57 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2018
First posted
Nov 1, 2018
StartActual
Jun 4, 2019
Primary completionActual
Jan 15, 2025
CompletionActual
Jan 15, 2025
Results first posted
Feb 4, 2026
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03727880
Lead sponsor
Lei Zheng
Responsible party
Lei Zheng (Executive Director of University of Texas Health Science Center at San Antonio Cancer Center, The University of Texas Health Science Center at San Antonio) — Sponsor-investigator
First posted
Nov 1, 2018
Start date
Jun 4, 2019
Primary completion
Jan 15, 2025
Completion
Jan 15, 2025
Results posted
Feb 4, 2026
Last update
Feb 4, 2026

Study contacts

Lei Zheng, MD
principal investigator · The University of Texas Health Science Center San Antonio
Arsen Osipov, MD
study chair · Cedar Sinai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Defactinib

Start the discussion